Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
about
Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryTardive dyskinesia: therapeutic options for an increasingly common disorder.New treatments for the motor symptoms of Parkinson's disease.Parkinson's Disease and Its Management: Part 4: Treatment of Motor ComplicationsSystems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Motor complications in Parkinson's disease.L-DOPA and graft-induced dyskinesia: different treatment, same story?Non-dopaminergic treatments for motor control in Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsWhat are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.Emerging drugs for levodopa-induced dyskinesia.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice.A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
P2860
Q26851517-0140C573-3A1F-40A6-93A8-E4EAFC8A7251Q30566749-ED827735-51C7-4184-B9F3-9C0390A6A983Q34443682-E49E46BF-4209-43D5-AE9E-0B8708C639E7Q36251899-1852BA5C-E27B-46AE-80CF-1F572D7B1AECQ36735012-E25E014E-C082-40CE-9D8E-BBFBDDE56731Q37924629-479721D8-C8FE-4615-91BA-5398DB4874C9Q37950426-31CE5F64-8D18-4D16-A007-F52EFE62EFE3Q38119449-BD6350A1-BF8C-4B52-94AD-DDB423623425Q38126817-A5BDCA02-8E1C-4C53-BBF5-33475443A8BAQ38156760-318EF0EC-E888-4A06-A822-C2944B43BE8CQ38212033-FDA69C1A-A07A-4D9B-A173-7CE38A9194CCQ38242091-752B4F0A-C121-4E3D-A99B-D506A0FE6FFBQ38262418-6CA77DDF-0574-4332-AE7D-408AE9CDCCC7Q39324877-0C5320B9-2914-4968-AD24-C10A4497A7B0Q41645312-C73BC19C-455D-48C9-A74B-7E07CAC7415EQ52147727-04FE48EA-3116-481B-8D28-A5C86B2C6A6FQ58649211-D7240BD9-4F24-4B87-8D35-4FC5847B702B
P2860
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Levetiracetam for levodopa-ind ...... ind, placebo-controlled trial.
@en
Levetiracetam for levodopa-ind ...... ind, placebo-controlled trial.
@nl
type
label
Levetiracetam for levodopa-ind ...... ind, placebo-controlled trial.
@en
Levetiracetam for levodopa-ind ...... ind, placebo-controlled trial.
@nl
prefLabel
Levetiracetam for levodopa-ind ...... ind, placebo-controlled trial.
@en
Levetiracetam for levodopa-ind ...... ind, placebo-controlled trial.
@nl
P2093
P2860
P921
P1476
Levetiracetam for levodopa-ind ...... ind, placebo-controlled trial.
@en
P2093
Alexander Storch
Christine Schneider
Johannes Schwarz
Karl Strecker
Martin Wolz
Matthias Löhle
Uta Schwanebeck
Xina Grählert
P2860
P2888
P304
P356
10.1007/S00702-010-0472-X
P577
2010-08-29T00:00:00Z
P6179
1048473018